OR WAIT null SECS
May 10, 2024
Studies conducted by a team at Oxford Biomedica demonstrated that HIC can be used to effectively separate non-deamidated capsids from deamidated capsids.
Regeneron’s work in CAR-T cell therapy development includes engineering receptor architecture to improve CAR-T cell sensitivity and improve immune response.
Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, Regeneron spoke about the use of bispecific antibodies to retarget AAV specificity.
May 08, 2024
Broken String Biosciences and the Francis Crick Institute will collaborate on research into how genome stability impacts ALS.
The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.
The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.
Experiments conducted by the downstream technology team at Spark Therapeutics involving metal ion-containing additives showed improved capsid clearance in AAV production.
May 06, 2024
Under a partnership, ProPharm and PBL have launched the Cell Factory Box, an enclosed and fully automated cell factory manufacturing device.
The collaboration will target solid tumors using Poseida’s allogeneic CAR-T platform to develop convertibleCAR programs.
May 03, 2024
Mariana’s portfolio of radioligand therapies will strengthen Novartis’ radioligand therapy pipeline.